The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis

被引：0
|
作者：
Mikhael, Joseph R. [1 ]
Schuster, Steven R. [1 ]
Jimenez-Zepeda, Victor H. [2 ]
Bello, Nancy [1 ]
Spong, Jacy [1 ]
Reeder, Craig B. [1 ]
Stewart, A. Keith [1 ]
Bergsagel, P. Leif [1 ]
Fonseca, Rafael [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1263 / 1263
页数：1
相关论文
共 6 条
  • [1] Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    Mikhael, Joseph R.
    Schuster, Steven R.
    Jimenez-Zepeda, Victor H.
    Bello, Nancy
    Spong, Jacy
    Reeder, Craig B.
    Stewart, A. Keith
    Bergsagel, P. Leif
    Fonseca, Rafael
    BLOOD, 2012, 119 (19) : 4391 - 4394
  • [2] Cyclophosphamide-bortezomib-dexamethasone (CYBORD) is highly effective in producing rapid and complete responses in patients with AL amyloidosis not eligible for transplant
    Mikhael, J.
    Jimenez-Zepeda, V. H.
    Reeder, C. B.
    Stewart, A. K.
    Bergsagel, P. L.
    Fonseca, R.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 171 - 171
  • [3] Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)
    Valent, Jason
    Silowsky, John
    Kurman, Michael R.
    Daniel, Eileen
    Jobes, Janet
    Harnett, Mark
    Ziola, Margaret
    Roviwong, Jessica
    Fada, Sherry
    Spector, Michael
    Sobolov, Susan B.
    BLOOD, 2020, 136
  • [4] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) plus /- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
    Kusne, Yael
    Fonseca, Rodrigo
    Arribas, Mariano
    Klanderman, Molly
    Wiedmeier, Julia E.
    Reeder, Craig B.
    Larsen, Jeremy T.
    Bergsagel, P. Leif
    Rosenthal, Julie L.
    Fonseca, Rafael
    BLOOD, 2022, 140 : 7224 - 7225
  • [5] Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
    Kyriakou, C
    Thomson, K
    D'Sa, S
    Flory, A
    Hanslip, J
    Goldstone, AH
    Yong, KL
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) : 763 - 770
  • [6] THE COMBINATION OF LENALIDOMIDE WITH LOW DOSE DEXAMETHASONE AND CYCLOPHOSPHAMIDE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH PRIMARY SYSTEMIC (AL) AMYLOIDOSIS: RESULTS OF A PHASE 1/2 STUDY
    Roussou, M.
    Kastritis, E.
    Gavriatopoulou, M.
    Migkou, M.
    Pamboukas, K.
    Gogos, D.
    Liapis, K.
    Michalis, E.
    Delimpasi, S.
    Psimenou, E.
    Toumanidis, S.
    Kontoyannis, S.
    Terpos, E.
    Dimopoulos, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 392 - 392
1